Key facts
- ShiraTronics’s last known valuation is $142.0M.
- It has raised $111.7M across 2 recorded rounds; the latest was Early Stage VC ($37.4M) in Sep 2024.
- Notable investors include Norwest, OSF Ventures, Amzak Health, Aperture Venture Partners, Breakout Ventures — 11 tracked in total.
- ShiraTronics has filed 4 Form Ds with the SEC since 2019, most recently Sep 2024 ($37.4M sold to 30 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for ShiraTronics
Funding rounds
2 roundsAbout ShiraTronics
Developer of novel neuromodulation technologies designed to treat unmet neurology-based clinical needs. The company's technology offers continuous stimulation to targeted nerves associated with migraine, potentially relieving, interrupting, and preventing chronic migraine symptoms, enabling patients to combat debilitating migraine headaches effectively.
- Sector
- Healthcare
- HQ
- Minneapolis, MN, United States
- Founded
- 2018
- Employees
- 35
- Website
- shiratronics.com/
- Ownership
- Privately Held (backing)
ShiraTronics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ShiraTronics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ShiraTronics in its N-PORT filings yet. We sweep new filings monthly.